scholarly journals Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer

BMC Surgery ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Takuki Yagyu ◽  
Hiroaki Saito ◽  
Teruhisa Sakamoto ◽  
Ei Uchinaka ◽  
Masaki Morimoto ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Mean Platelet Volume ◽  
Poor Prognosis ◽  
Characteristic Curve ◽  
Prognostic Indicator ◽  
Carbohydrate Antigen ◽  
Long Term Outcomes ◽  
Platelet Volume ◽  
Serum Carbohydrate Antigen

Abstract Background Decreased mean platelet volume (MPV) predicts poor prognosis in some cancers. However, its significance as a prognostic indicator in pancreatic cancer (PC) remains unclear. Methods A total of 91 PC patients who underwent pancreatectomy were included in this study. MPV and serum carbohydrate antigen 19-9 (CA19-9) were measured within 1 week before surgery. Results We divided patients into MPVhigh (≥ 8.65; n = 40), MPVlow (< 8.65; n = 51), CA19-9high (≥ 66.3; n = 47), and CA19-9low (< 66.3; n = 44) groups based on the optimal cut-off values determined from receiver operating characteristic curve analysis. The 5-year overall survival (OS) rates were significantly lower in the MPVlow than in the MPVhigh group (16.9% and 56.3%, respectively; P = 0.0038), and the 5-year disease-specific survival (DSS) rates in the MPVlow group and MPVhigh group were 20.5% and 62.2%, respectively (P = 0.0031). Multivariate analysis identified MPV as an independent prognostic indicator for both OS and DSS. The patients were then divided into groups A (MPVhigh and CA19-9low), B (MPVhigh and CA19-9high), C (MPVlow and CA19-9low), and D (MPVlow and CA19-9high), with 5-year OS rates of 73.2%, 40.4%, 25.8%, and 10.3%, respectively (P = 0.0002), and 5-year DSS rates of 80.8%, 44.9%, 27.3%, and 16.4%, respectively (P = 0.0003). Conclusions Classification based on MPV and CA19-9 might be useful for predicting long-term outcomes in patients with PC.

Usefulness of Mean Platelet Volume as a Biomarker for Long-Term Outcomes After Percutaneous Coronary Intervention

2011 ◽  
Vol 107 (2) ◽  
pp. 204-209 ◽  
Author(s):  
Sandro Cadaval Goncalves ◽  
Marino Labinaz ◽  
Michel Le May ◽  
Chris Glover ◽  
Michael Froeschl ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Mean Platelet Volume ◽  
Coronary Intervention ◽  
Long Term Outcomes ◽  
Platelet Volume ◽  
Percutaneous Coronary

scholarly journals Mean Platelet Volume/Lymphocyte Ratio as a Prognostic Indicator for HBV-Related Decompensated Cirrhosis

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
JianPing Wu ◽  
WeiLin Mao ◽  
XinKe Li
Keyword(s):  
Mean Platelet Volume ◽  
Characteristic Curve ◽  
Prognostic Indicator ◽  
Prognostic Scores ◽  
Decompensated Cirrhosis ◽  
Multivariate Logistic Regression Model ◽  
Platelet Volume ◽  
Lymphocyte Ratio ◽  
B Virus ◽  
Poor Outcomes

Aim. To evaluate the prognostic role of the mean platelet volume/lymphocyte ratio (MPVLR) for mortality in patients with hepatitis B virus-related decompensated cirrhosis (HBV-DeCi). Methods. The medical records of 101 patients with HBV-DeCi were retrospectively reviewed, and their baseline clinical and laboratory characteristics were extracted. The predictive value of the MPVLR for death was estimated using receiver operating characteristic curve analysis and a multivariate logistic regression model. Results. Patients with HBV-DeCi in the high-MPVLR group exhibited significantly increased 90-day mortality compared with that of the patients within the low-MPVLR group, and MPVLR was an independent predictor of 90-day mortality in patients with HBV-DeCi. Conclusions. Increased MPVLR is associated with poor outcomes in patients with HBV-DeCi and might be a useful component of future prognostic scores.

Acute and Chronic Changes in Platelet Volume and Count After Cardiopulmonary Bypass Induced Thrombocytopenia in Man

1987 ◽  
Vol 57 (01) ◽  
pp. 55-58 ◽  
Author(s):  
J F Martin ◽  
T D Daniel ◽  
E A Trowbridge
Keyword(s):  
Platelet Count ◽  
Mean Platelet Volume ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Control Group ◽  
Artery Bypass Graft ◽  
Platelet Volume ◽  
Young Males ◽  
The Mean

SummaryPatients undergoing surgery for coronary artery bypass graft or heart valve replacement had their platelet count and mean volume measured pre-operatively, immediately post-operatively and serially for up to 48 days after the surgical procedure. The mean pre-operative platelet count of 1.95 ± 0.11 × 1011/1 (n = 26) fell significantly to 1.35 ± 0.09 × 1011/1 immediately post-operatively (p <0.001) (n = 22), without a significant alteration in the mean platelet volume. The average platelet count rose to a maximum of 5.07 ± 0.66 × 1011/1 between days 14 and 17 after surgery while the average mean platelet volume fell from preparative and post-operative values of 7.25 ± 0.14 and 7.20 ± 0.14 fl respectively to a minimum of 6.16 ± 0.16 fl by day 20. Seven patients were followed for 32 days or longer after the operation. By this time they had achieved steady state thrombopoiesis and their average platelet count was 2.44 ± 0.33 × 1011/1, significantly higher than the pre-operative value (p <0.05), while their average mean platelet volume was 6.63 ± 0.21 fl, significantly lower than before surgery (p <0.001). The pre-operative values for the platelet volume and counts of these patients were significantly different from a control group of 32 young males, while the chronic post-operative values were not. These long term changes in platelet volume and count may reflect changes in the thrombopoietic control system secondary to the corrective surgery.

Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer

2017 ◽  
Vol 49 (4) ◽  
pp. 481-486 ◽  
Author(s):  
Pedro L. S. Usón Junior ◽  
Donato Callegaro-Filho ◽  
Diogo D. G. Bugano ◽  
Fernando Moura ◽  
Fernando C. Maluf
Keyword(s):  
Pancreatic Cancer ◽  
Predictive Value ◽  
Advanced Pancreatic Cancer ◽  
Carbohydrate Antigen ◽  
Early Mortality ◽  
Serum Carbohydrate Antigen

scholarly journals Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

Cancer ◽  
2011 ◽  
Vol 118 (12) ◽  
pp. 3026-3035 ◽  
Author(s):  
Nils D. Arvold ◽  
David P. Ryan ◽  
Andrzej Niemierko ◽  
Lawrence S. Blaszkowsky ◽  
Eunice L. Kwak ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer ◽  
Long Term Outcomes

scholarly journals Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis

2020 ◽  
Vol 27 (1) ◽  
pp. 107327482097659
Author(s):  
Wentao Zhou ◽  
Dansong Wang ◽  
Wenhui Lou
Keyword(s):  
Pancreatic Cancer ◽  
Liver Metastasis ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Synchronous Liver Metastasis ◽  
Long Term Outcomes ◽  
Short And Long Term ◽  
Current Guidelines

Pancreatic cancer with synchronous liver metastasis has an extremely poor prognosis, and surgery is not recommended for such patients by the current guidelines. However, an increasing body of studies have shown that concurrent resection of pancreatic cancer and liver metastasis is not only technically feasible but also beneficial to the survival in the selected patients. In this review, we aim to summarize the short- and long-term outcomes following synchronous liver metastasectomy for pancreatic cancer patients, and discuss the potential criteria in selecting appropriate surgical candidates, which might be helpful in clinical decision-making.

Sign in / Sign up

Export Citation Format

Share Document